🇺🇸 FDA
Patent

US 9675692

Stabilized formulations containing anti-DLL4 antibodies

granted A61KA61K39/39533A61K39/39591

Quick answer

US patent 9675692 (Stabilized formulations containing anti-DLL4 antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K39/39533, A61K39/39591, A61P, A61P17/06